Expression of nitric oxide synthase and transforming growth factor-beta in crush-injured tendon and synovium. by Darmani, Horma et al.
THIS study examined the expression of inducible
nitric oxide synthase (iNOS) and transforming
growth factor-beta (TGF-b) in macrophage infiltrates
within crush-injured digital flexor tendon and syno-
vium of control rats and rats treated with N(G)-nitro-
l-arginine methyl ester (L-NAME) (5 mg/kg). Release
of TGF-b from organ cultures of tendon, muscle, and
synovium, and the effects of L-NAME treatment (in
vitro and in vivo), on adhesion of peritoneal macro-
phages to epitenon monolayers were also investi-
gated. The results showed that during normal tendon
healing the levels of TGF-b are high at first and
gradually decrease after 3 weeks of injury to slightly
above control uninjured levels. However, when
L-NAME was administered at the time of injury, the
macrophage infiltrates were expressing high levels of
TGF-b even at 5 weeks after the injury, with no
evidence of reduction. In the standard injury, iNOS
activity was greatest at the acute phase of the
inflammatory response and then gradually returned
to normal. Treatment with L-NAME, however, re-
sulted in inhibition of iNOS activity at 3 days and a
reduction in the activity at the later time points
examined after injury. We also found greatly in-
creased levels of adhesion of peritoneal macrophages
from L-NAME-treated rats to epitenon monolayers
in vitro, which reflect a chronic imbalance in
expression of TGF-b, which is overexpressed, and
nitric oxide, which is underexpressed. The results of
the current study show that formation of nitric oxide
is an important event in the course of tendon healing
since its inhibition results in chronic inflammation
and fibrosis due to an imbalance in TGF-b expression
in vivo.
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Introduction
Following tendon injuries, post-trauma fibrous adhe-
sions bind adjacent synovial tissue to injured tendon
resulting in subsequent pain, stiffness and disability.
It is well established that transforming growth factor-
beta (TGF-b) plays an important role in wound
healing and fibrosis,
1 and modulation of TGF-b
production in tendon healing may provide a mechan-
ism to modulate adhesion formation clinically.
2
During the early stages of wound healing, down-
regulation of this effector molecule by administration
of antibodies to TGF-b1 may reduce adhesion
formation between injured tendon and synovium.
3
TGF-b has been reported to induce the inhibition
of nitric oxide production by macrophages through
decreasing the stability and translation of mRNA for
the enzyme nitric oxide synthase and increasing its
degradation.
4 Nitric oxide, a highly reactive free
radical produced from the amino acid arginine by
the enzyme nitric oxide synthase,
5 has recently been
reported to play a multitude of roles in the regulation
of wound healing.
6 10 Furthermore, inhibition of
nitric oxide synthesis has been reported to lead to a
decrease in the formation of granulation tissue by
wound cells.
8 Indeed, nitric oxide, known for its
pleiotropic effects, has also been reported as a
potentially important antifibrotic molecule.
11 13
We have recently studied the effect of inhibition of
nitric oxide production, at the time of injury, on
inflammatory cell accumulation and fibrosis around
the digital flexor tendon and synovium.
14 We found
that the incidence and severity of fibrocellular adhe-
sions between the tendon and synovium was much
more marked in animals treated with N(G)-nitro-L-
arginine methyl ester (L-NAME), which elicited
a chronic inflammatory response characterised by a
persistent and extraordinarily severe accumulation of
large numbers of inflammatory cells in the subcuta-
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299neous tissues, in muscle and in tendon. We suggested
that these findings could have been indicative of
a chronic imbalance in the expression of TGF-b
(likely to be overexpressed) and nitric oxide (likely
to be underexpressed). In this study we examine
the expression of inducible nitric oxide synthase
(iNOS) and TGF-b at different stages of the healing
process in standard and L-NAME-treated crush-in-
jured rat digital flexor tendon and synovium. We also
measure the release of TGF-b from organ cultures of
tendon, muscle and synovium and examine the
effects of L-NAME treatment (in vitro and in vivo)
on adhesion of peritoneal macrophages to epitenon
monolayers.
Materials and methods
Reagents
Tissue culture reagents were purchased from Gibco
BRL (Life Technologies, Paisley, UK). All other
reagents were purchased from Sigma Chemical Co.
(Poole, UK), unless otherwise stated.
Animal model
Female Wistar rats weighing in the range of 250 /300
g were anaesthetised using Halothane, and under
tourniquet control a longitudinal incision was made
in the plantar surface of the hindpaw and extended
along the line of the middle digit to expose the
synovial canal. A standard crush injury was then
applied with Adson’s forceps along the length of
the flexor tendons of the middle digit of the hindpaw
and the overlying muscle and synovium. The wound
was sutured using a continuous nylon suture and
the animals were allowed to mobilise without restric-
tion following the procedure. The animals were
then sacrificed by CO2 asphyxiation followed by
cervical dislocation at various time points following
injury.
Control uninjured group
Five animals were sacrificed for histology and five
animals for TGF-b determinations by enzyme-linked
immunosorbent assay (ELISA).
Crush injury group
Twenty animals received an intraperitoneal injection
of isotonic saline immediately following crush injury.
Five animals were then sacrificed after 3 days and 2
and 5 weeks, and the paws were then processed for
histology. Peritoneal macrophages were isolated
from these animals for the adhesion assay. The
remaining five animals were sacrificed after 3 days
for TGF-b determinations by ELISA.
Crush injury group treated with L-NAME.
Twenty-five animals received an intraperitoneal in-
jection of L-NAME (5 mg/kg) immediately following
the crush injury. Five animals were then sacrificed
after 3 days and 2 and 5 weeks, and the paws were
then processed for histology. Peritoneal macro-
phages from these L-NAME-treated rats were isolated
for the adhesion assay. Another group of five animals
was sacrificed after 3 days and 5 weeks for determi-
nations of TGF-b levels by ELISA.
Preparation of specimens for tissue
immunohistochemistry
Tissue was prepared for histological examination by
undertaking a block dissection to include the
wounded skin, subcutaneous tissues, tendon, syno-
vium and muscle, all of which were carefully
dissected from the underlying bones. The dissected
tissues were pinned onto cork to achieve good
alignment of the tendons and were then fixed in
10% neutral buffered formalin and processed for
tissue immunohistochemistry.
Tissue immunohistochemistry
Block dissected specimens, treated as already de-
scribed, were embedded in OCT medium (Miles Inc.,
Elkhart, IN, USA) and frozen to   /708C. Longitudinal
sections, 5 mm in thickness, were cut onto slides,
allowed to reach room temperature, and then pro-
cessed for immunohistochemical staining of cells
expressing TGF-b and iNOS.
Immunohistochemical staining for TGF-b
The sections were washed in Tris-buffered saline
(TBS), and treated with dilute normal serum for
15 min. The slides were then drained and incubated
with anti-TGF-b (prepared in TBS and bovine serum
albumin) for 1 h at room temperature. After washing
three times in TBS for 5 min, the slides were treated
with biotin-conjugated secondary antibody for
45 min at room temperature. Subsequent to three
further 5-min washes in TBS, the sections were
incubated with alkaline phosphate-conjugated extra-
vidin (Sigma) at a dilution of 1:1000 for 30 min. The
sections were washed three times in TBS and then
visualised using fast 5-bromo-4-chloro-3 indolyl
phosphate/nitro blue tetrazolium substrate (Sigma).
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The sections were washed in TBS, and were treated
with dilute normal serum for 15 min. The slides were
then drained and incubated with anti-iNOS (prepared
in TBS and bovine serum albumin) for 1 h at room
temperature. After washing three times in TBS for
5 min, the slides were processed as already described
for TGF-b.
Preparation of specimens for TGF-b
determinations
Dissected tissue (wounded skin, subcutaneous tis-
sues, tendon, synovium and muscle) was carefully
separated from the underlying bones. The tissue was
minced into small pieces and gently disrupted using a
pestle and mortar. Organ cultures were then main-
tained in serum-free RPMI 1640 supplemented with
100 mg/ml of penicillin, 100 U/ml of streptomycin,
2.85 mM glutamine and bicarbonate for 24 h at 378C.
The accumulation of TGF-b was quantitated using
ELISA.
Quantification of TGF-b by ELISA
TGF-b levels were quantified in tissue culture super-
natants using an ELISA kit (Predicta human cytokine
ELISAs for TGF-b; Genzyme, Cambridge, MA, USA).
Samples and standards were first diluted and acid-
ified using hydrochloric acid for 1 h and were
then neutralised to pH 7.0 /7.4 with sodium hydrox-
ide. Tissue culture fluid and tissue extract were
diluted with an equal volume of sample diluent.
Then 100 ml of activated standards (0, 0.1, 0.64, 1.6,
and 4.0 ng/ml) and samples were added to a
microtitre plate precoated with a mouse monoclonal
antibody to TGF-b, and the plate was sealed and
incubated at 378C for 609 /2 min. The samples were
then aspirated and the wells washed vigorously with
six changes of wash buffer. Excess fluid was then
removed by blotting on tissue paper and 100 mlo f
anti-TGF-b horseradish peroxidase conjugate was
then added and the plate sealed and incubated at
378C for 609 /2 min. The liquid was then aspirated
and the wells washed vigorously with six changes of
wash buffer. After blotting off excess fluid with tissue,
100 ml of substrate reagent (tetramethylbenzidine
(B /2%) in solvent (B /40%) and 0.03% hydrogen
peroxide in buffered solution) was added to each
well and the plate was left at room temperature for
209 /1 min. Next, 100 ml of stop solution (acid
mixture;B /2 N) was added and the absorbance was
recorded at 450 nm using a BioRad multiscan
microtitre plate reader (Bio-Rad Laboratories, Rich-
mond, CA, USA). A standard curve was then con-
structed to quantitate TGF-b concentrations in the
samples.
Cell culture
Epitenon cells. Rat epitenon fibroblasts were isolated
from the flexor tendons of young adult male
Sprague /Dawley rats according to the method of
Banes et al.,
15 as described previously.
16 Cell mono-
layers were grown to confluence in Glasgow mod-
ified Eagle’s medium (MEM) supplemented with 10%
calf serum, 100 mg/ml of penicillin, 100 U/ml of
streptomycin, 2.85 mM glutamine and bicarbonate.
Peritoneal macrophage cultures. Control and L-
NAME-treated rats were sacrificed by CO2 asphyxia-
tion followed by cervical dislocation. Macrophages
were obtained from control and L-NAME-treated rats
by peritoneal lavage by injection of 20 ml of sterile
phosphate-buffered saline (PBS) into the peritoneal
cavity. Following a gentle massage of the abdomen,
peritoneal macrophages were collected and any
contaminating erythrocytes were removed by hypo-
tonic lysis. The cells were then washed twice by
centrifugation at 2000 r.p.m. for 2 min and finally
resuspended in serum-free RPMI medium, for adhe-
sion assays. For one part of the study, macrophages
were treated with different concentrations of L-NAME
(0 /1.85 mM) for 24 h at 378C before being used for
the adhesion assay.
Adhesion assay
A suspension of peritoneal macrophages in serum-
free RPMI medium was applied onto quiescent,
confluent monolayers of rat epitenon cells in 24-
well plates (total volume, 500 ml/well). After incuba-
tion for a variable length of time the suspension was
aspirated, and the monolayers were rinsed three
times with sterile PBS. The total number of adherent
monocytes was evaluated by a colourimetric assay
17
of fixed cells stained with crystal violet. Following co-
incubations of epitenon monolayers with macro-
phages for 6 h, the cultures were washed three times
in order to remove non-adherent macrophages. They
were then fixed with a solution of 1% glutaraldehyde
in PBS for 15 min at room temperature. The cultures
were then air-dried and stained with 0.1% (w/v)
solution of crystal violet for 30 min at room tempera-
ture. The crystal violet was aspirated and the mono-
layers were washed in three changes of sterile
distilled water. Cells were permeabilised with 1%
Triton X-100 overnight. Aliquots of the resulting
solution, containing solubilised nuclear staining crys-
tal violet were transferred to 96-well microtitre plates
and subjected to absorbance spectrometry at 595 nm
with a Bio-Rad model 450 microplate reader (Bio-Rad
Laboratories, Richmond, CA, USA). Absorbance was
found to be proportional to macrophage density after
normalisation for the absorbance of parallel, non-co-
incubated rat epitenon cell monolayers.
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Expression of iNOS in the healing tendon
We first looked at iNOS expression in macrophage
infiltrates within tissue sections taken from control
uninjured rat paws, standard crush-injured rat paws
and L-NAME-treated crush-injured rat paws (Table 1).
Histological sections of control uninjured paws,
immunocytochemically labelled with anti-iNOS anti-
body, showed basal levels (  /) of nitric oxide activity.
The iNOS activity in crush injured paws, taken from
animals sacrificed 3 days subsequent to injury, at the
acute phase of the inflammatory response, was
greatly raised (  /  /  /) and then gradually returned
to normal. When L-NAME had been administered
immediately at the time of injury, iNOS activity was
abolished ( /) in the 3-day crush-injured paws. The
iNOS activity in sections taken from 5-week crush-
injured paws from animals that had received L-NAME
treatment was still weaker (9 /) than that seen in
sections of control uninjured paws (  /).
Expression of TGF-b in the healing tendon
We next looked at the levels of TGF-b expression in
macrophage infiltrates within tissue sections taken
from control uninjured rat paws, standard crush-
injured rat paws and L-NAME-treated crush-injured
rat paws (Table 1). In uninjured paws, the synovium
and subsynovial tissues did not stain for TGF-b. Since
the tendon matrix normally acts as a repository for
this cytokine, there was some evidence of TGF-b
staining (9 /). Sections of crush-injured paws showed
that the majority of the inflammatory cells were
expressing TGF-b, and a strong positive (  /  /  /)
staining was observed. The expression of TGF-b in
sections of crush-injured paws taken from animals
decreased gradually, and by 5 weeks subsequent to
injury the TGF-b levels were reduced further but still
slightly above that observed in control uninjured
paws (  /). When L-NAME was administered at the
time of injury, a strong expression of TGF-b by
inflammatory cells was observed at 3 days after injury
(  /  /  /), and this increase was maintained 5 weeks
after injury (  /  /  /).
Concentration of TGF-b in tissue extracts
We next measured the amounts of TGF-b using ELISA
from tissue culture supernatants of the tendon,
muscle and synovium. Fig. 1 shows the levels of
TGF-b in control, crush-injured and L-NAME-treated
crush-injured paws. TGF-b concentrations in crush-
injured paws are doubled in comparison with the
levels in uninjured paws. Tissue extracts from crush-
injured paws showed a 212% increase in TGF-b
levels. This is in agreement with the increased
staining for TGF-b observed in tissue sections of
injured paws. When L-NAME was administered im-
mediately at the time of injury, there was a 33%
reduction in the TGF-b levels, in comparison with
crush-injured paws that had not received L-NAME, at
the acute phase of the inflammatory response. The
levels of TGF-b in tissue extracts from paws taken 5
weeks after injury and L-NAME administration were
found to be comparable with those in control
uninjured paws.
Effects of in vitro inhibition of iNOS on adhesion
of macrophage cells to epitenon monolayers
Since we had previously found that in vivo treatment
with L-NAME resulted in a greater degree of inflam-
matory cell adhesion to tendon and synovium,
14 we
next looked at the effects of L-NAME treatment of
macrophage cells on their subsequent adhesion to
epitenon monolayers.
Figure 2 shows the adhesion of peritoneal macro-
phages to quiescent monolayers of rat epitenon cells.
Pre-treatment of macrophages with different concen-
trations of L-NAME induced statistically significant
increases in the adhesion of macrophages to epite-
non monolayers, in comparison with control macro-
phages that had not been pre-treated with L-NAME.
Table 1. Expression of iNOS and TGF-b in the healing tendon
of standard and L-NAME-treated animals after crush injury of
the rat digital ﬂexor tendon and synovium
Treatment iNOS TGF-b
Control L-NAME Control L-NAME
Uninjured 9 /   /
Crush injury
3 days   /  /  /   /  /  /   /  /  /   /
2 weeks   /  /   /  /  /   /  /   /
5 weeks   /   /  /  /   / 9 /
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FIG. 1. TGF-b concentrations in tendon organ cultures from
control uninjured rat paws, crush-injured rat paws (3 days
after injury) and crush-injured rat paws with L-NAME treat-
ment (3 days and 5 weeks after injury). Error bars represent
standard error of the means. **pB /0.005 versus control
uninjured paws, and
##pB /0.01 versus 3-day crush-injured
paws.
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to have a much greater effect on peritoneal macro-
phage adhesiveness.
Effects of in vivo inhibition of iNOS on adhesion
of peritoneal macrophages to epitenon
monolayers
We also wished to find out whether the in vivo
administration of L-NAME at the time of injury
affected the adhesiveness of peritoneal macrophages,
and to test this we isolated macrophages from control
and L-NAME-treated rats at 3 days, 2 weeks and 5
weeks of L-NAME administration. Fig. 3 shows the
adhesion of peritoneal macrophages to quiescent
monolayers of rat epitenon cells. Peritoneal macro-
phages taken from rats that had been treated with L-
NAME for 3 days showed a statistically significant
(pB /0.0005) increase in adhesiveness to epitenon
monolayers in comparison with control untreated
rats. This increased adhesiveness was still evident at 2
and 5 weeks after L-NAME treatment, although the
results were not statistically significant after 5 weeks.
Discussion
The pathophysiology of adhesion formation follow-
ing tendon injury involves the accumulation of large
numbers of inflammatory cells around the injured
tendon and synovium, which release many cytokines
and growth factors within the healing wound. TGF-b
is one of the most important cytokines in the healing
wound since it appears to control the level of tissue
fibrosis
18 20 and, indeed, its expression in a variety of
tissues has been directly linked to areas of fibro-
sis.
19,21 We have demonstrated in this study that
inhibition of nitric oxide synthesis at the time of
injury leads to a chronic overexpression of TGF-b in
vivo. In control injuries, TGF-b expression was
increased in macrophages at the acute phase of the
inflammatory response, and during the next 2 weeks
subsequent to injury remained elevated, and by 3
weeks the TGF-b levels decreased gradually to
slightly above that observed in control uninjured
paws. Inhibition of nitric oxide production by
administration of L-NAME at the time of injury upset
the balance and macrophages were still expressing
high levels of TGF-b at 5 weeks after the injury with
no evidence of any reduction in its activity, in vivo.I t
is well established that chronic elevation of TGF-b
levels in the healing wound will lead to increased
deposition of collagen by stimulated fibroblasts and
this chronic accumulation of collagen in the healing
tendon and synovium is critical in the progressive
loss of function in tendon healing. The fibrotic
process is tightly regulated by many factors including
cytokines and circulating hormones, and the role of
nitric oxide in the control of fibrosis and adhesion
formation is just beginning to be investigated.
We have demonstrated that inflammatory cell
infiltration into tendon, muscle and synovial tissue
coincides with an increase in iNOS activity in macro-
phage cells. The increase in iNOS activity is greatest
at the acute phase of the inflammatory response and,
as the latter subsides, the iNOS activity returns to
normal. Treatment with L-NAME resulted in inhibi-
tion of iNOS activity at 3 days and a reduction in the
activity at the later time points examined after injury.
Inhibition of iNOS activity during the early stages of
tendon wound healing resulted in a chronic inflam-
matory response seen as late as 5 weeks after injury.
14
This was reflected in our results of TGF-b expression
within the healing tendon, which showed that
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FIG. 2. Adhesion of control and L-NAME-pretreated rat
peritoneal macrophages to quiescent monolayers of rat
epitenon cells. Macrophages had been pretreated with
different concentrations of L-NAME for 24 h. Error bars
represent standard error of the means. **pB /0.005 and
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FIG. 3. Adhesion of peritoneal macrophages taken from
control and L-NAME-treated rats to quiescent monolayers
of rat epitenon cells. Error bars represent standard error of
the means. **pB /0.0025 and ***pB /0.0005 versus macro-
phages taken from control untreated rats.
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expression of TGF-b in vivo. Nitric oxide may thus be
important in exerting some sort of control on TGF-b
levels in the initial phase of tendon healing.
Craven et al.
22 reported that nitric oxide actually
suppresses TGF-b expression by inducing a marked
reduction in total and active TGF-b bioactivity in
mesangial cells cultured in 5.6 or 30 mmol/l of
glucose and it also suppresses increases in TGF-b
mRNA in response to culture in high concentrations
of glucose. Furthermore, nitric oxide has also been
reported to be antiproliferative and antifibrotic for
mesangial cells in vitro.
23 28
During the early phase of wound healing, nitric
oxide may thus act to downregulate activity of the
fibrogenic cytokine TGF-b in the healing tendon.
Indeed, the production of nitric oxide during wound
healing has been reported to be important in the
successful outcome of healing and, due to its many
faceted biological functions, nitric oxide may delay
wound repair during the early phase, but may
promote healing during the more mature phase.
8 10
Studies on arginine metabolism in a rat wound
healing model have demonstrated a biphasic pattern
where the initial inflammatory phase was marked by
activation of the L-arginine/nitric oxide pathway with
an increase in nitric oxide synthase activity over the
first 2 /3 days after wounding, and this was followed
by arginase activity during the repair phase.
29,30
During the early phase of wound healing when nitric
oxide synthase activity is at its highest, nitric oxide
may decrease inflammatory cell adherence and
transendothelial migration, and induce apoptosis in
macrophages and thus reduce the inflammatory cell
presence.
Although nitric oxide at nanomolar concentrations
is cytoprotective, at micromolar concentrations it is
cytotoxic and contributes to cell injury in a variety of
disease states.
31 33 Cytokines like TGF-b that are
centrally involved in tissue repair are potent inhibi-
tors of iNOS expression and therefore play a role in
teminating nitric oxide-dependent tissue injury.
11 In
cultured rat mesangial cells nitric oxide significantly
inhibits collagen and fibronectin synthesis and in-
creases activity of the matrix degrading enzyme
gelatinase, which should decrease fibrotic matrix
accumulation.
24 26 The repair promoting cytokine
TGF-b significantly increases the activity of macro-
phage and fibroblast arginase,
34,35 and thus this
cytokine may play a role in decreased cytotoxic nitric
oxide production and increased repair-oriented L-
ornithine production. The suppression of nitric oxide
is probably as important to its regulation as its
induction, and the regulatory actions of TGF-b on
iNOS may be critical for controlling inflammation.
36,37
In turn, a potential regulatory effect of nitric oxide on
TGF-b expression at the initial phase of tendon
healing may be as critical on the outcome of
successful healing.
The greatly increased levels of adhesion of inflam-
matory cells to tendon and muscle in vivo and to
epitenon monolayers in vitro in our L-NAME studies
reflect a chronic imbalance in expression of TGF-b,
which is overexpressed, and nitric oxide, which is
underexpressed. The physiological significance of
nitric oxide biosynthesis in the course of tendon
repair is only beginning to be elucidated. We have
shown that formation of nitric oxide is an important
event in the course of tendon healing since its
inhibition results in chronic inflammation and fibrosis
due to an imbalance in TGF-b expression in vivo.
References
1. Border WA, Noble NA. Transforming growth factor b in tissue ﬁbrosis. N
Engl J Med 1994; 331: 1286 /1292.
2. Klein MB, Yalamanchi N, Pham H, Longaker MT, Chang J. Flexor tendon
healing in vitro: effects of TGF-beta on tendon cell collagen production.
J Hand Surg [Am] 2002; 27: 615 /620.
3. Chang J, Thunder R, Most D, Longaker MT, Lineaweaver WC. Studies in
ﬂexor tendon wound healing: neutralizing antibody to TGF-beta1
increases postoperative range of motion. Plast Reconstr Surg 2000;
105: 148 /155.
4. Gilbert RS, Herschman HR. Transforming growth factor beta differen-
tially modulates the inducible nitric oxide synthase gene in distinct cell
types. Biochem Biophys Res Commun 1993; 195:3 8 0 /384.
5. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J
1994; 298: 249 /258.
6. Shi HP, Most D, Efron DT, Tantry U, Fischel MH, Barbul A. The role of
iNOS in wound healing. Surgery 2001; 130: 225 /229.
7. Lin JH, Wang MX, Wei A, Zhu W, Diwan AD, Murrell GA. Temporal
expression of nitric oxide synthase isoforms in healing Achilles tendon. J
Orthop Res 2001; 19: 136 /142.
8. Schaffer MR, Tantry U, Gross SS, Wasserkrug HL, Barbul A. Nitric oxide
regulates wound healing. JS u r gR e s1996; 63:2 3 7 /240.
9. Schaffer MR, Tantry U, Thornton FJ, Barbul A. Inhibition of nitric oxide
synthesis in wounds: pharmacology and effect on accumulation of
collagen in wounds in mice. Eur J Surg 1999; 165:2 6 2 /267.
10. Schaffer M, Weimer W, Wider S, Stulten C, Bongartz M, Budach W,
Becker HD. Differential expression of inﬂammatory mediators in
radiation-impaired wound healing. JS u r gR e s2002; 107:9 3 /100.
11. Peters H, Noble NA. Dietry L-arginine in renal disease. Seminars Nephrol
1996; 16: 567 /575.
12. Ferrini MG, Vernet D, Magee TR, Shahed A, Qian A, Rajfer J, Gonzalez-
Cadavid NF. Antiﬁbrotic role of inducible nitric oxide synthase. Nitric
Oxide 2002; 6: 283 /294.
13. Peters H, Daig U, Martini S, et al. NO mediates antiﬁbrotic actions of L-
arginine supplementation following induction of anti-thy1 glomerulone-
phritis. Kidney Int 2003; 64: 509 /518.
14. Darmani H, Crossan JC, Curtis A. Single dose of iNOS inhibitor induces
prolonged inﬂammatory cell accumulation and ﬁbrosis around injured
tendon and synovium. Mediat Inﬂamm 2004; 13: 157 /164.
15. Banes AJ, Donlon K, Link GW, et al. Cell populations of tendon*/a
simpliﬁed method for isolation of synovial cells and internal ﬁbroblasts:
conﬁrmation of origin and biologic properties. J Orthopaed Res 1988; 6:
83 /94.
16. Wojciak B, Crossan J. The accumulation of inﬂammatory cells in synovial
sheath and epitenon during adhesion formation in healing rat ﬂexor
tendons. Clin Exp Immunol 1993; 93: 108.
17. Westergren-Thorsson G, Onnervik PO, Fransson LA, Malmstrom A.
Proliferation of accumulated ﬁbroblasts is inhibited by L-iduronate-
containing glycosaminoglycans. J Cell Physiol 1991; 147:5 2 3 /530.
18. Wahl SM. Transforming growth factor beta in inﬂammation. A cause and
a cure. J Clin Immunol 1992; 12: 61.
19. Brahmatewari J, Seraﬁni A, Serralta V, Mertz PM, Eaglstein WH. The
effects of topical transforming growth factor-beta2 and anti-transforming
growth factor-beta 2,3 on scarring in pigs. J Cutan Med Surg 2000; 4:
126 /131.
20. Chamberlain J. Transforming growth factor-beta: a promising target for
anti-stenosis therapy. Cardiovasc Drug Rev 2001; 19:3 2 9 /344.
21. Border WA, Ruoslahti E. Transforming growth factor-b in disease: the
dark side of tissue repair. J Clin Invest 1992; 90:1 /7.
H. Darmani et al.
304 Mediators of Inflammation Vol 13  200422. Craven PA, Struder RK, Felder J, Phillips S, DeRubertis FR. Nitric oxide
inhibition of transforming growth factor-b and collagen synthesis in
mesangial cells. Diabetes 1997; 46:6 7 1 /681.
23. Garg UC, Hassid A. Inhibiting of rat mesangial cell mitogenesis by nitric
oxide-generating vasodilators. Am J Physiol 1989; 257:F 6 0 /F66.
24. Trachtman H, Futterweit S, Singhal P. Nitric oxide modulates the
synthesis of extracellular matrix proteins in cultured rat mesangial cells.
Biochem Biophys Res Commun 1995; 207: 120 /125.
25. Trachtman H, Futterweit S, Garg P, Reddy K, Singhal PC. Nitric oxide
stimulates the activity of a 72kda neutral matrix metalloproteinase in
cultured rat mesangial cells. Biochem Biophys Res Commun 1996; 218:
704 /708.
26. Trachtman H, Futterweit S, Singhal PC, Franki N, Sharma M, Sharma R,
Savin V. Circulating factor in patients with recurrent focal segmental
glomerulosclerosis postrenal transplantation inhibits expression of
inducible nitric oxide synthase and nitric oxide production by cultured
rat mesangial cells. J Investig Med 1999; 47: 114 /120.
27. Chin TY, Lin YS, Chueh SH. Antiproliferative effect of nitric oxide on rat
glomerular mesangial cells via inhibition of mitogen-activated protein
kinase. Eur J Biochem 2001; 268: 6358 /6368.
28. Keil A, Blom IE, Goldschmeding R, Rupprecht HD. Nitric oxide down-
regulates connective tissue growth factor in rat mesangial cells. Kidney
Int 2002; 62: 401 /411.
29. Albina JE, Mills CD, Barbul A, Thirkill CE, Henry WL, Mastrofrancesco B,
Caidwell MD. Arginine metabolism in wounds. Am J Physiol 1988; 17:
E459 /E467.
30. Albina JE, Mills CD, Henry WL, Caldwell MD. Temporal expression of
different pathways of L-arginine metabolism in healing wounds. J
Immunol 1990; 144: 3877 /3880.
31. Lefer DJ, Scalia R, Campbell B, et al. Peroxynitrite inhibits leukocyte-
endothelial cell interactions and protects against ischemia-reperfusion
injury in rats. J Clin Invest 1997; 99: 684 /691.
32. Ma XL, Gao F, Lopez BL, Christopher TA, Vinten-Johansen J. Peroxyni-
trite, a two-edged sword in post-ischemic myocardial injury-dichotomy
of action in crystalloid- versus blood-perfused hearts. J Pharmacol Exp
Ther 2000; 292: 912 /920.
33. Zweier JL, Fertmann J, Wei G. Nitric oxide and peroxynitrite in
postischemic myocardium. Antioxid Redox Signal 2001; 3:1 1 /22.
34. Boutard V, Havouis R, Fouqueray B, Philippe C, Moulinoux JP, Baud L.
Transforming growth factor-beta stimulates arginase activity in macro-
phages. Implications for the regulation of macrophage cytotoxicity. J
Immunol 1995; 155: 2077 /2084.
35. Witte MB, Barbul A, Schick MA, Vogt N, Becker HD. Upregulation of
arginase expression in wound-derived ﬁbroblasts. JS u r gR e s2002; 105:
35 /42.
36. Vodovotz Y, Bogdan C, Paik J, Xie Q-W, Nathan C. Mechanisms of
suppression of macrophage nitric oxide release by transforming growth
factor-b. J Exp Med 1993; 178: 605 /613.
37. Vodovotz Y. Control of nitric oxide production by transforming growth
factor-beta1: mechanistic insights and potential relevance to human
disease. Nitric Oxide 1997; 1:3 /17.
Received 4 May 2004
Accepted 6 July 2004
NOS and TGF-b in crush-injured tendon and synovium
Mediators of Inflammation Vol 13  2004 305